CERT Stock Overview
Provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CERT from our risk checks.
Certara, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.31 |
52 Week High | US$19.87 |
52 Week Low | US$10.35 |
Beta | 1.5 |
11 Month Change | -11.98% |
3 Month Change | -17.08% |
1 Year Change | -21.51% |
33 Year Change | -68.61% |
5 Year Change | n/a |
Change since IPO | -70.30% |
Recent News & Updates
Certara: Still Awaiting Consistent Growth
Sep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 31Recent updates
Certara: Still Awaiting Consistent Growth
Sep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 31There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price
Jul 18Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital
Jun 13When Should You Buy Certara, Inc. (NASDAQ:CERT)?
Apr 11Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk
Mar 21Returns Are Gaining Momentum At Certara (NASDAQ:CERT)
Feb 17Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
Jan 30Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Dec 07Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Oct 31Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Sep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued
Aug 30Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue
Aug 03Certara: A Story To Watch
Sep 27Certara to raise capital in secondary stock offering
Aug 12Shareholder Returns
CERT | US Healthcare Services | US Market | |
---|---|---|---|
7D | 5.5% | 0.2% | 2.6% |
1Y | -21.5% | 3.1% | 30.5% |
Return vs Industry: CERT underperformed the US Healthcare Services industry which returned 1.8% over the past year.
Return vs Market: CERT underperformed the US Market which returned 27.6% over the past year.
Price Volatility
CERT volatility | |
---|---|
CERT Average Weekly Movement | 7.1% |
Healthcare Services Industry Average Movement | 9.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CERT's share price has been volatile over the past 3 months.
Volatility Over Time: CERT's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,365 | Bill Feehery | www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
Certara, Inc. Fundamentals Summary
CERT fundamental statistics | |
---|---|
Market cap | US$1.76b |
Earnings (TTM) | -US$78.68m |
Revenue (TTM) | US$363.55m |
5.0x
P/S Ratio-23.1x
P/E RatioIs CERT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CERT income statement (TTM) | |
---|---|
Revenue | US$363.55m |
Cost of Revenue | US$149.01m |
Gross Profit | US$214.55m |
Other Expenses | US$293.23m |
Earnings | -US$78.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.49 |
Gross Margin | 59.01% |
Net Profit Margin | -21.64% |
Debt/Equity Ratio | 28.4% |
How did CERT perform over the long term?
See historical performance and comparison